Core Viewpoint - IQVIA Holdings Inc. is set to release its first-quarter 2025 results on May 6, with expectations of revenue growth and earnings per share increase compared to the previous year [1][4]. Revenue Expectations - The Zacks Consensus Estimate for total revenues is $3.8 billion, reflecting a slight year-over-year increase [2]. - Revenues from Research and Development Solutions (R&DS) are anticipated to be $2.1 billion, indicating a 1.6% rise from the previous year [2]. - Technology and Analytics Solutions (TAS) revenues are estimated at $1.5 billion, suggesting a 1% year-over-year growth [3]. - Contract sales and Medical solutions' revenues are projected to be $192 million, implying a 1.8% growth from the year-ago quarter [3]. Earnings Expectations - The consensus estimate for earnings per share is $2.63, suggesting a 3.5% increase year-over-year [4]. - The adjusted EBITDA for the first quarter is estimated at $886.6 million, indicating a 2.9% year-over-year growth [4]. Earnings Prediction Model - The current model does not predict a definitive earnings beat for IQVIA, with an Earnings ESP of -0.27% and a Zacks Rank of 4 (Sell) [5].

Core Insights - Wall Street analysts anticipate IQVIA Holdings (IQV) to report quarterly earnings of $2.63 per share, reflecting a year-over-year increase of 3.5% [1] - Expected revenues for the quarter are projected at $3.77 billion, which represents a 0.9% increase from the previous year [1] Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised downward by 0.1%, indicating a collective reassessment by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions to the stock, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock price performance [3] Revenue Projections - Analysts estimate 'Revenues- Technology & Analytics Solutions' to be $1.52 billion, indicating a year-over-year increase of 4.4% [5] - The consensus for 'Revenues- Research & Development Solution' is projected at $2.08 billion, suggesting a decline of 0.9% year over year [5] - 'Revenues- Contract Sales & Medical Solutions' is expected to reach $183.42 million, reflecting a year-over-year decrease of 3% [5] Segment Profit Estimates - The estimated 'Backlog' for IQVIA is $31.43 billion, up from $30.1 billion in the same quarter last year [6] - Analysts project 'Segment Profit- Technology & Analytics Solution' to be $365.56 million, an increase from $335 million reported in the same quarter last year [6] - 'Segment Profit- Contract Sales & Medical Solutions' is expected to be $15.65 million, compared to $13 million in the same quarter last year [7] - The average prediction for 'Segment Profit- Research & Development Solutions' is $471.69 million, slightly down from $479 million reported in the same quarter last year [7] Stock Performance - IQVIA shares have decreased by 11.1% over the past month, contrasting with a decline of 0.7% in the Zacks S&P 500 composite [7] - With a Zacks Rank of 4 (Sell), IQV is expected to underperform the overall market in the near term [7]

The market expects IQVIA Holdings (IQV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be release ...

Core Insights - NVIDIA has launched the Llama Nemotron family of models, which are designed to provide advanced AI reasoning capabilities for developers and enterprises [1][4] - The new models enhance multistep math, coding, reasoning, and complex decision-making through extensive post-training, improving accuracy by up to 20% and optimizing inference speed by 5x compared to other leading models [2][3] Model Features - The Llama Nemotron model family is available in three sizes: Nano, Super, and Ultra, each tailored for different deployment needs, with the Nano model optimized for PCs and edge devices, the Super model for single GPU throughput, and the Ultra model for multi-GPU servers [5] - The models are built on high-quality curated synthetic data and additional datasets co-created by NVIDIA, ensuring flexibility for enterprises to develop custom reasoning models [6] Industry Collaboration - Major industry players such as Microsoft, SAP, and Accenture are collaborating with NVIDIA to integrate Llama Nemotron models into their platforms, enhancing AI capabilities across various applications [4][7][8][10] - Microsoft is incorporating these models into Azure AI Foundry, while SAP is using them to improve its Business AI solutions and AI copilot, Joule [7][8] Deployment and Accessibility - The Llama Nemotron models and NIM microservices are available as hosted APIs, with free access for NVIDIA Developer Program members for development, testing, and research [12] - Enterprises can run these models in production using NVIDIA AI Enterprise on accelerated data center and cloud infrastructure, with additional tools and software to facilitate advanced reasoning in collaborative AI systems [16]

Investment Rating - The report rates Thermo Fisher as "Buy" with a target price indicating a potential upside of 31.8% [2] Core Insights - The performance of C(D)MO and life sciences upstream companies is showing positive trends, while clinical CRO companies are experiencing a decline in demand [1][4] - The overall revenue and profit growth for the tracked companies in 2024 remains under pressure, but half of them showed improvement in the second half of 2024 compared to the first half [6][7] - The demand outlook for 2025 varies significantly across different segments, with C(D)MO and life sciences upstream companies being optimistic, while clinical CRO companies maintain a cautious stance [1][4][38] Summary by Sections Profit Recovery - Profit recovery is outpacing revenue recovery, with the median and average profit growth rates for the industry in 2024 at +2.4% and +3.5%, respectively, compared to -6.2% and -7.2% in 2023 [7][24] - The average gross margin for the tracked companies decreased from 46.4% in 2022 to 41.7% in 2024, indicating pressure from demand weakness [24][25] Demand Trends - C(D)MO companies are witnessing strong commercial production demand, with Lonza and Samsung Bio reporting significant growth in their C(D)MO revenues [38][39] - Life sciences upstream companies are benefiting from the completion of inventory destocking by downstream clients, leading to a recovery in demand [39][40] 2025 Performance Guidance - C(D)MO and life sciences upstream companies are providing improved performance guidance for 2025, while clinical CRO companies are showing a notable deterioration in their outlook [1][4][39] - Lonza expects its C(D)MO revenue growth to approach 20% in 2025, while Samsung Bio anticipates a continued growth of 20-25% [1][4] Long-term Growth Support - The global healthcare financing is stabilizing, with a 1.4% year-on-year increase in 2024, marking the first positive growth since 2021 [1][4] - Pharmaceutical companies' strong free cash flow will continue to support innovation and research and development [1][4] Market Reactions - Following the 4Q24 earnings releases, stock price reactions varied significantly across different segments, with C(D)MO and clinical pre-CRO stocks performing better than life sciences upstream and clinical CRO stocks [30][31]

Core Insights - The clinical trials market is projected to grow from US$ 58.39 billion in 2024 to US$ 99.25 billion by 2033, with a CAGR of 6.07% from 2025 to 2033, driven by various factors including healthcare demands and technological advancements [1][18]. Growth Drivers - The rising incidence of chronic illnesses is increasing the demand for effective treatment development, with significant global prevalence of diseases such as diabetes and cancer [3][4][5]. - The acceptance of decentralized clinical trials (DCTs) is enhancing patient participation and reducing logistical costs, making trials more efficient and patient-centered [6][7]. - The shift towards personalized medicine is expected to improve drug development success rates by utilizing pharmacogenetics, leading to increased investments in clinical trials by biopharmaceutical companies [8][9]. Market Dynamics - Phase III trials hold the largest market share due to their extensive patient involvement and higher costs, averaging over USD 19.0 million per trial [14]. - Oncology is the leading indication segment in the clinical trials market, attributed to the high prevalence of cancer and the number of ongoing trials [16]. - Interventional studies are projected to dominate the market, driven by the need for improved diagnostics and vaccines for viral diseases [17]. Challenges - Ethical and regulatory issues pose significant challenges for clinical trials, particularly those involving animal-based products, leading to increased costs and delays [10][11]. - Long trial durations and variability in individual responses complicate the clinical trial process, necessitating larger sample sizes and more complex methodologies [12][13].

Core Insights - Certara, Inc. has appointed Adrian McKemey, Ph.D. as President of Drug Development Solutions to enhance its strategic drug development solutions [1][2] - McKemey brings over 25 years of experience in R&D roles, focusing on business transformation and portfolio management [2] - The leadership change is part of a planned transition, with Patrick Smith continuing as Senior Vice President of Translational Sciences [3] Group 1 - Adrian McKemey's leadership is expected to scale Certara's biosimulation and scientific services, supporting the development of next-generation therapies [4] - Certara's expertise in biosimulation is crucial for addressing challenges in clinical development and improving success rates in drug portfolios [4] - The company serves over 2,400 clients, including biopharmaceutical companies and regulatory agencies across 66 countries [5]

证券代码：600196 股票简称：复星医药 编号：临 2025-029 上海复星医药（集团）股份有限公司 关于控股子公司获药品注册申请受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公司重庆 药友制药有限责任公司就盐酸溴己新注射液（以下简称"该药品"）的药品注册申 请于近日获国家药品监督管理局受理。 二、该药品的基本信息及研究情况 盐酸溴己新注射液为本集团（即本公司及控股子公司/单位，下同）自主研发的 化学药品。该药品拟用于在口服给药困难的情况下，以下疾病和症状的祛痰：肺结 核、尘肺病、手术后。 三、风险提示 该药品在进行商业化生产前，尚需（其中主要包括）获得药品注册批准等。本 次获药品注册申请受理不会对本集团现阶段业绩产生重大影响。 1 由 IQVIA 提供，IQVIA 是全球医药健康产业专业信息和战略咨询服务提供商；IQVIA CHPA 数据代表中国境 内 100 张床位以上的医院药品销售市场，不同的药品因其各自销售渠道布局的不同，实际销售情 ...

| --- | --- | |-----------------------|-------| | | | | | | | | | | Q4 2021 Earnings Call | | | February 15, 2022 | | IQVIA Template (V2.1.0) Legal IQVIA Template (V2.1.0) 1 This presentation should be viewed in conjunction with IQVIA's Q4 2021 earnings call Safe Harbor Statement for Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Secur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-35907 IQVIA HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpor ...